AbbVie (ABBV) Q3 2026 (Fri Oct 30 premarket) — net revenues <meta name="viewport" content="width=device-width, initial-scale=1.0" />7.404B (+10.3% rpt / +10.5% operational) beats ~<meta name="viewport" content="width=device-width, initial-scale=1.0" />7.3B est; GAAP diluted EPS $2.37; adjusted diluted EPS $3.82; Immunology $9.165B (+16.3%) with Skyrizi $5.776B (+22.7%) and Rinvoq $2.706B (+23.9%); Humira $683M (-31.2%); Neuroscience $3.389B (+19.4%) with Vraylar <meta name="viewport" content="width=device-width, initial-scale=1.0" />.068B (+14.3%); Oncology <meta name="viewport" content="width=device-width, initial-scale=1.0" />.696B (+0.8%); Aesthetics <meta name="viewport" content="width=device-width, initial-scale=1.0" />.176B (-1.4%) with Botox Cosmetic $669M (+4.9%); raises FY26 adjusted diluted EPS guide to <meta name="viewport" content="width=device-width, initial-scale=1.0" />3.95–<meta name="viewport" content="width=device-width, initial-scale=1.0" />3.99 (from <meta name="viewport" content="width=device-width, initial-scale=1.0" />3.76–<meta name="viewport" content="width=device-width, initial-scale=1.0" />3.96); hikes quarterly dividend 5.2% to <meta name="viewport" content="width=device-width, initial-scale=1.0" />.82/share payable February 16 2027; completed Apogee Therapeutics acquisition in Q3 with $408M pre-tax acquisition and integration costs ($391M after-tax, $0.22/share impact); stock +2.0% intraday to ~$296.53

7.4B revenue as Skyrizi (+23%) and Rinvoq (+24%) propel Immunology; raises FY26 adj EPS guide and lifts dividend 5.2%." /> 7.404B (+10.3% rpt / +10.5% operational) beats ~7.3B est; GAAP diluted EPS $2.37; adjusted diluted EPS $3.82; Immunology $9.165B (+16.3%) with Skyrizi $5.776B (+22.7%) and Rinvoq $2.706B (+23.9%); Humira $683M (-31.2%); Neuroscience $3.389B (+19.4%) with Vraylar .068B (+14.3%); Oncology .696B (+0.8%); Aesthetics .176B (-1.4%) with Botox Cosmetic $669M (+4.9%); raises FY26 adjusted diluted EPS guide to 3.95–3.99 (from 3.76–3.96); hikes quarterly dividend 5.2% to .82/share payable February 16 2027; completed Apogee Therapeutics acquisition in Q3 with $408M pre-tax acquisition and integration costs ($391M after-tax, $0.22/share impact); stock +2.0% intraday to ~$296.53" /> 7.4B revenue as Skyrizi (+23%) and Rinvoq (+24%) propel Immunology; raises FY26 adj EPS guide and lifts dividend 5.2%." /> 7.404B (+10.3% rpt / +10.5% operational) beats ~7.3B est; GAAP diluted EPS $2.37; adjusted diluted EPS $3.82; Immunology $9.165B (+16.3%) with Skyrizi $5.776B (+22.7%) and Rinvoq $2.706B (+23.9%); Humira $683M (-31.2%); Neuroscience $3.389B (+19.4%) with Vraylar .068B (+14.3%); Oncology .696B (+0.8%); Aesthetics .176B (-1.4%) with Botox Cosmetic $669M (+4.9%); raises FY26 adjusted diluted EPS guide to 3.95–3.99 (from 3.76–3.96); hikes quarterly dividend 5.2% to .82/share payable February 16 2027; completed Apogee Therapeutics acquisition in Q3 with $408M pre-tax acquisition and integration costs ($391M after-tax, $0.22/share impact); stock +2.0% intraday to ~$296.53" /> 7.4B revenue as Skyrizi (+23%) and Rinvoq (+24%) propel Immunology; raises FY26 adj EPS guide and lifts dividend 5.2%." />

Stock/TLDR — What Just Moved Markets: Earnings, Fed, M&A, MoversA high-volume feed of market-moving releases — quarterly earnings, FOMC decisions, M&A, regulatory actions, big single-name moves, macro prints, commodities and crypto — refreshed every 12 hours. Each release is explained in plain English so you actually understand what just happened and which tickers it touches.This site uses JavaScript to render the interactive feed. Enable JavaScript to use it.Stock/TLDR is not investment advice. Verify everything against primary sources before trading.